Importantly these findings open up the possibility of utilizing anti-androgens in the treatment of a specific subtype of breast cancer expressing high levels of AR and PSAP, which may not exhibit sustained response to endocrine therapy. The gene discussed is PSAP; the disease is breast carcinoma.